Psivant

Curated by Signal

Developer of therapeutics for cancer and immunology disorders

Overview

Developer of therapeutics for cancer and immunology disorders. It offers an IRAK inhibitor for inflammation, a WEE1 selective inhibitor for cancer, and an allosteric inhibitor for inflammation and immunology. It has QUAISAR computational platform that combines computational physics and artificial intelligence for drug discovery.

Key facts

Founded: 2022
Headquarters: Boston, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Contact

Email: Sign up to view

Open roles

1 role

Create Your Own Role!
Boston, MA · On-site · Full-time

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Lantern Pharma
Developing drug and companion diagnostics for multi-drug resistant cancers
Life Sciences TechnologyDallas, United States
Invoy
Developer of an app-connected breath monitors to measure and plot fat burn number
Life Sciences TechnologyChandler, United States
QUiCKR Bio
Developer of a biotechnology platform to provide near real-time quantification of genetic modification
Life Sciences TechnologyRedwood City, United States

About Psivant

What does Psivant do?

Developer of therapeutics for cancer and immunology disorders.

Where is Psivant headquartered?

Psivant is headquartered in Boston, United States.

When was Psivant founded?

Psivant was founded in 2022.

Which sector is Psivant in?

Psivant operates in Life Sciences Technology.

Who are Psivant's competitors?

Companies similar to Psivant include Lantern Pharma, Invoy, and QUiCKR Bio.

Is Psivant hiring?

Yes. Psivant has 1 open role listed on Vanberra Signal.